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Abstract
Background:  In Zambia, unacceptably high resistance to commonly used antimalarial drugs
prompted the choice of artemether-lumefantrine (AL) as first line treatment for uncomplicated
Plasmodium falciparum malaria. Although the safety and efficacy of AL have been extensively
documented, no clinical trials had been carried out in Zambia.
Methods: Nine hundred seventy one adult patients with uncomplicated malaria were randomized
to either sulfadoxine-pyrimethamine (SP)(486) or AL (485) and followed up for 45 days. Outcome
of treatment was defined according to the standard WHO classification. Recurrent parasitaemia
were genotyped to distinguish between recrudescence and new infection.
Results: Fever at day 3 was significantly lower (AL: 0.9%; 4/455; SP: 3,5%; 15/433; p = 0.007) and
the mean haemoglobin at day 45 significantly higher (AL: 134 g/l; SP 130 g/l; p = 0.02) in the AL
group. Almost all clinical symptoms cleared faster with AL. Early treatment failure was significantly
higher in the SP (25/464) than in the AL (2/463) (OR: 13.1 95% CI: 3.08–55.50; P < 0.001). The rate
of new infections was similar in both groups (18 with SP and 19 with AL). Late clinical failure (OR:
2.55; 95% CI: 1.34–4.84; P = 0.004) and late parasitological failure (OR:3.18; 95% CI: 1.25–8.09; P
= 0.02) were significantly higher in the SP group. Total treatment failure was significantly higher in
the SP group (96/393; 19.3%) as compared to the AL (22/403; 5.4%) group (OR: 4.15; 95% CI: 2.52–
6.83; P < 0.001).
Conclusion: In Zambia, the new first line regimen AL is far more efficacious than SP in treating
uncomplicated P. falciparum malaria in adults. Data on safety and efficacy of AL in pregnant women
are urgently needed.
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Background
In Zambia, malaria treatment and control have been
undermined by the emergence of resistance to commonly-
used antimalarial drugs such as chloroquine (CQ) and
sulfadoxine-pyrimethamine (SP)[1]. Unacceptably high
resistance to commonly used antimalarial drugs
prompted the choice of artemether-lumefantrine (AL) as
first line treatment for uncomplicated Plasmodium falci-
parum malaria. Zambia was the first African country to
adopt an artemisinin-based combination treatment as its
national policy. The safety of AL has been extensively
reviewed [2]and several trials, in Africa all of them in chil-
dren, have demonstrated its efficacy [3-10]. AL exists as a
fixed tablet formulation and it has been registered in a
large number of countries under the names of Coartem® or
Riamet®. The fixed tablet formulation helps to overcome
problems of compliance associated with non-coformu-
lated combinations.
The results of a randomized clinical trial on the efficacy of
SP compared to AL in adult patients with uncomplicated
malaria in Ndola, Zambia, are reported below. Patients
were followed up for 45 days.
Methods
Study participants
The study started in March 2003, during the antimalarial
drug policy transition from SP to AL, and was completed
in June 2005. Patients were recruited at 4 peri-urban
health centers in Ndola, Zambia, an area of mesoendemic
malaria where transmission is perennial with a seasonal
peak from November to April. A reliable ambulance serv-
ice is available and patients requiring hospitalization can
be referred to Ndola Central Hospital, about 5 km away.
All individuals aged 15–50 years attending any of the 4
peri-urban clinics and presenting with fever (body tem-
perature ≥ 37.5°C), and/or history of fever in the previous
48 hours, and without any other obvious disease were
screened for malaria infection (thick and thin blood film
in duplicate for parasite density and species identifica-
tion) and pregnancy (if applicable). Patients with a P. fal-
ciparum density of 25/200 WBC (assumed to be 1,000
parasites/µl) or more were included. Exclusion criteria
were the following: pregnancy, severe falciparum malaria
[11], documented intake of SP or AL or another sulfa-drug
in the two weeks prior to recruitment, other cause of fever,
evidence of underlying chronic diseases (cardiac, renal,
hepatic, malnutrition), history of allergy to study drug or
known allergy to other sulpha drugs such as cotrimoxazol,
and being non-resident in the study area. Written
informed consent (in English and in Bemba) was
obtained prior to recruitment from each patient. The eth-
ical and scientific committees of the Institute of Tropical
Medicine, Antwerp, Belgium, and the Tropical Disease
Research Centre, Ndola approved the study.
Enrolment, treatment and follow up
Patients were randomly allocated by blocks of 10 (accord-
ing to a pre-established list) to receive either SP (Fan-
sidar®, Roche: 500 mg sulfadoxine/25 mg pyrimethamine
tablets), single dose of 3 tablets (2.5 tablets if < 50 kg), or
AL (Coartem®, Novartis: 20 mg artemether/120 mg lume-
fantrine tablets), 4 tablets immediately followed by 4 tab-
lets at 8, 24, 36, 48 and 60 hours, taken with a creamy
snack. Treatment allocation was concealed until final
recruitment. SP treatment was directly observed and
patients were monitored at the health centre for at least 30
minutes after treatment. For AL, the morning doses were
directly observed over the 3 days of treatment, while the
evening doses were given to the patients to be taken at
home, and empty sachets returned as evidence of taking
the drug. Paracetamol tablets (3 doses/day for 2 days)
were provided, to be taken when needed.
Clinical history, signs and symptoms, body temperature
were recorded and a blood sample for parasitaemia
(blood slide) and for molecular analysis (on Schleicher &
Schuell filter paper) were collected at days 0, 3, 7, 14, 21,
28 and 45 or at any unscheduled visit. The blood sample
on filter paper was dried at room temperature and stored
at -20°C with silica gel. At day 0 (before treatment), a
drop of venous blood was collected for Hb measurement
(HaemoCue®). Hb was measured again at day 14 and 45.
Patients were encouraged to attend the health facility out-
side scheduled visits if they felt ill. Patients treated with SP
and classified as failures (clinical or parasitological) were
treated with AL, while those on AL received quinine.
Adverse events were documented and treated accordingly.
Patients were excluded during follow up for the following
reasons: self-administration of other antimalarial drugs,
emergence of any concomitant febrile illness that inter-
fered with outcome classification, development of hyper-
sensitivity to the study drug, withdrawal of informed
consent.
Laboratory investigations
All lab technicians were blinded to the patient's identity
and all patient-related parameters. Thin blood films were
fixed with methanol and thin and thick blood films were
stained with 10% Giemsa. At the clinic, the number of
asexual P. falciparum parasites per 200 white blood cells
(WBC) was determined. Parasite density per µl was com-
puted taking into account the actual WBC counts. Internal
quality control was organized as recommended by the
WHO [11]. Hb was assessed with Haemocue® and noted
with a precision of 0.1 g/dl. Blood samples collected on
filter paper at enrolment and during follow up were used
to genotype parasite strains; only those microscopically
positive after day 14 were analysed. DNA was purified as
described previously [12] and a nested PCR for the analy-Malaria Journal 2006, 5:73 http://www.malariajournal.com/content/5/1/73
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sis of two polymorphic P. falciparum genetic markers
MSP1 and MSP2 repeat region was carried out. A recrudes-
cent infection was defined as one that showed match in
size of at least one allele for both the MSP1 and MSP2
genes between the first and second sample.
Assessment of outcome
Outcome of treatment was defined according to the stand-
ard WHO classification (WHO 2003): Early Treatment
Failure (ETF) was defined as: i) danger signs of/or severe
malaria on days 1, 2 or 3 with parasitaemia; ii) parasite
density at day 2 greater than at day 0; iii) parasitaemia on
day 3 with axillary temperature ≥ 37.5°C and iv) parasite
density at day 3 equal or greater than 25% of that at day
0. Late Clinical Failure (LCF) was defined as danger signs
of/or severe malaria and/or parasitaemia with axillary
temperature ≥ 37.5°C between day 4 and day 45, without
having been previously classified as ETF. Late parasitolog-
ical failure (LPF) was defined as reappearance of parasitae-
mia between day 4 and day 45 without fever and without
previously meeting any of the criteria for ETF or LCF. An
adequate clinical and parasitological response (ACPR)
was defined as absence of parasitaemia by day 45 without
previously meeting any of the criteria for ETF, LCF and
LPF. The overall rate of treatment failure (Total Treatment
Failure TTF) was computed as if the patient had an ETF,
LCF or a LPF. Only parasitaemia confirmed by PCR as
recrudescence was considered as treatment failure.
Patients were also considered treatment failures if they
received rescue treatment on or before day 45. As both
drugs were registered and used in Zambia, no stopping
rules were defined.
All adverse events (AEs) were recorded on the Case Record
Form (CRF). An AE was defined as "any unfavorable and
unintended sign, symptom, or disease temporally associ-
ated with the use of the drug administered". A causality
assessment of the AEs was done according to the guide-
lines of WHO-Uppsala Monitoring Centre (WHO-UMC).
Statistical analysis
Data were double entered and cleaned in Epi-info (ver-
sion 6.04b; Centre for Disease Control and Prevention).
All analyses were performed using STATA statistical anal-
ysis software package version 8 (Stata Corp., College Sta-
tion, TX, USA, 2003). Proportions were compared using
the χ2 or Fisher's exact test (when required); Student's t-
test was used for continuous variables. Paired t-test was
used for within patient comparisons. All reported p-value
are two-sided. Non-parametric tests (Wilcoxon or
Kruskal-Wallis) were used for non-normally distributed
variables. For the intention-to-treat analysis the log-rank
test and the Hazard Ratio (Cox regression) were estimated
after testing for proportional hazard assumption (Schoen-
feld test). Data of the patients excluded or lost to follow
up were censored at the time of the last recorded visit. All
possible interactions up to order two were tested.
Results
Enrollment
Between March 2003 and June 2005, a total of 971
patients were randomized to either SP (486) or AL (485).
At enrolment the 2 groups had similar demographic and
clinical characteristics (Table 1). Body temperature was
significantly associated with parasite density (P < 0.001).
Trial profile
By day three, 35 (3.6%) patients were lost to follow up
and 120 (12.4%) by day 45; 12 patients withdrew and 9
were excluded (4 hospitalized for reasons not linked to
treatment or malaria and 5 took other antimalarial drugs).
The percentage of lost to follow up were similar in both
treatment arms (AL: 83/486 vs SP: 72/485. P = 0.41). The
main reason for withdrawal and loss to follow up (>80%)
was population movement. Patients excluded or lost dur-
ing follow up were younger (mean age 24.4 yr; P < 0.001)
but other demographic and clinical characteristics were
similar.
Analysis of efficacy
SP and AL were generally well tolerated. Almost all clinical
symptoms cleared faster with AL (Table 2). At day 3, the
prevalence of parasitaemia (AL:3/451,0.7%; SP:65/
433,15%,) (P < 0.0001) and fever (AL: 4/455,0.9%;SP:15/
433,3,5%) (P = 0.007) was significantly lower in the AL
than in the SP group (Table 2). PCR genotyping identified
18 (4.6% of LTF) new infections in the SP and 19 (4.7%
of LTF) in the AL group and these were considered as
ACPR. ETF was significantly higher in the SP (25/465)
than in the AL group (2/462) (OR:13.1; 95% CI: 3.08–
55.50; P < 0.001). SP was also a risk factor for LCF (OR:
2.55; 95% CI: 1.34–4.84; P = 0.004) and LPF (OR:3.18;
95%CI: 1.25–8.09; P  = 0.02) (Table 3). Overall, total
treatment failure was more than 4-fold higher in the SP
(74/391; 19.3%) than in the AL (22/404; 5.4%) group
(OR: 4.15; 95% CI: 2.52–6.83; P < 0.001) (Table 3). Aver-
age time to new infections was similar in both treatment
arms (AL:41.6 days vs SP:40.8 days; P = 0.76). Average
time to recrudescence was significantly different between
treatment arms (AL: 34.4 days vs SP: 22.7 days; P = 0.004).
Log-rank test and Cox regression gave identical results to
the per protocol analysis (Figure 2) (HR: 3.77; 95 % CI,
2.34 to 6.06; P < 0.001). Gametocyte carriage during fol-
low up was also significantly higher in the SP group (Table
2). By day 14 the mean Hb had decreased in both groups:
SP: -6.0 g/l (paired t-test: P < 0.001); AL: -2.3 g/l (P =
0.003). At day 45 mean Hb was significantly higher in the
AL (134 g/l) than in the SP (130 g/l) group (P = 0.02). By
day 45, compared to day 0, Hb had significantly increasedMalaria Journal 2006, 5:73 http://www.malariajournal.com/content/5/1/73
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in the AL (+ 2.7 g/l) (P = 0.02) but not in the SP group (-
0.5 g/l; P = 0.65) (Table 2).
Serious adverse events were observed in 2 patients treated
with SP (one hospitalized for severe headache received
quinine and one developed hypoglycemia) and one
treated with AL who developed a rash. Eleven patients (5
on AL and 6 on SP) had various symptoms possibly
related to the study drugs but none serious enough to
interrupt the treatment.
Discussion
This trial was conducted in Zambia where a six-dose regi-
men of AL has been recently implemented as the first line
treatment for uncomplicated malaria in non-pregnant
adults and children over 10 kg. However, SP was still the
standard therapy in March 2003 and this treatment was
used as control. AL was clearly better than SP for several
outcomes such as parasitological clearance, resolution of
symptoms and safety. Hb followed a similar pattern, the
drop observed at day 14 was more pronounced and the
hematological recovery by day 45 lower in the SP arm. As
expected, SP-treated patients had a significantly higher
prevalence of gametocytes even if some patients treated
with AL had gametocytes at day 28. These results confirm
previous findings [3-7,13,14] and support the policy
change with the 6-dose regime of AL recently imple-
mented in Zambia.
Despite the high cure rate, a similar rate of new infections
was observed in both treatment groups. This is a concern
as routine services do not make any distinction between
recrudescence and new infections. In this mesoendemic
study area, the ratio new infections/recrudescence was rel-
atively low but in places where the malaria transmission
is more intense it could increase substantially. The new
infections and the residual number of parasites of the 'old'
infection would be exposed to sub therapeutic doses of
lumefantrine, the long acting partner drug in the AL com-
bination, and this might increase the selection of resistant
strains [3]. Furthermore, low compliance might also con-
tribute to the selection of resistant strains [15]. Indeed, a
recent report from Zambia showed that even where drugs
were freely available and clinic staff knew they were being
observed, only 22% of patients eligible for ACTs actually
received them [16]. Furthermore, even if patients receive
AL, they might not comply correctly unless the impor-
tance of respecting the dosage is fully explained to them
[16]. It has been shown that AL treatment, can have high
cure rate irrespective of whether given under supervision
with food or under conditions of routine clinic practice
[17]. The recently observed increased tolerance to AL [18]
underlines the importance of setting up a good surveil-
Table 1: Baseline characteristics by treatment (%)
SP
N = 486
AL
N = 485
Mean weight (Kg) (SD) 56.4 (10.1) 56.3 (9.6)
Number of women (%) 245 (50.5) 230 (47.4)
Mean age (yr) (SD) 27.0 (8.9) 26.3 (8.3)
Mean body temperature (°C) (SD) 37.2 (1.2) 37.3 (1.3)
Mean white blood cell count (n*109/l) (SD)* 5.1 (1.8) 5.2 (1.8)
Mean Hb (g/l) (SD) 13.0 (2.2) 13.2 (2.3)
Mean (geometric) parasite density(/µl) (range)* 8787 (406 – 103680) 8405 (350–158894)
Gametocytes prevalence (n)(%) 16 (3.3) 18 (3.7)
N = 477 N = 481
Weakness (%) 344 (72.1) 365 (75.9)
Headache (%) 428 (89.7) 429 (89.2)
Muscle/joint pain (%) 316 (66.2) 318 (66.2)
Dizziness (%) 176 (36.9) 177 (36.7)
Nausea (%) 190 (39.9) 180 (37.5)
Vomiting (%) 104 (21.7) 113 (23.5)
Diarrhoea (%) 62 (13.1) 59 (12.2)
Abdominal pain (%) 172 (36.1) 163 (33.8)
Heart palpitations (%) 76 (16.0) 76 (15.7)
Backache (%) 105 (22.0) 119 (24.7)
Jaundice** (%) 51 (10.7) 104 (21.7)
Pallor** (%) 6 (1.3) 1 (0.3)
Dark urine (%) 51 (10.6) 48 (9.9)
*Data on WBC were missing in 4 patients in the SP group and in 7 in the AL group. Parasite density was calculated based on the parasites/WBC 
ratio.
** Jaundice and pallor in 302 patients in the SP and and 301 in the AL group.M
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Table 2: Clinical and parasitological evolution during follow up by treatment.
Day 3 Day 7 Day 14 Day 28
SP AL P SP AL P SP AL P SP AL P
N 430 451 405 436 384 406 290 320
Fever (%) 3.5 0.9 0.007 1.0 1.1 0.55 1.3 1.0 0.75 2.7 1.2 0.19
Parasitaemia 15.0 0.7 <0.001 2.0 0.0 NA 2, 0;5 0.009 5.5 1.2 0.003
Hemoglobin (mean)*(g/L) - - - - 124 129 0.003 130 134 0.02
Gametocyte carriage (N (%)) 33 (7.6) 3 (0.7) <0.001 88 (21.6) 2 (0.5) <0.001 76 (19.8) 0 (0) NA 10 (4.5) 1 (0,3) 0.004
Gametocyte densities (range) 48.6 (1–4320) 6.2 (1–240) 0.62 63.6 (1–4480) 8.9 (1–80) 0.51 52.8 (1–6960) 0(0) NA 154.9 (3–840) 160 NA
N 430 448 400 428 382 401 303 329
Weakness (%) 46.3 20.5 <0.001 15.0 6.1 <0.001 7.1 3.7 0.04 5.9 3.0 0.08
Headache (%) 45.6 22.5 <0.001 18.0 12.2 0.02 10.7 8.5 0.28 11.5 10.3 0.62
Muscle joint pain (%) 20.3 8.2 <0.001 5.2 2.6 0.004 3.8 2.8 0.47 2.3 2.8 0.73
Dizziness (%) 20.0 10.8 <0.001 5.2 3.0 0.11 2.1 1.0 0.21 2.7 1.2 0.18
Nausea (%) 15.8 2.9 <0.001 1.3 0.0 NA 0.8 0.5 NA 0.7 0.6 NA
Vomiting (%) 5.8 0.7 <0.001 0.5 0.2 NA 0.5 0.5 NA 0.0 0.3 NA
Diarrhoea (%) 3.8 7.7 0.013 0,9 2.5 0.08 1.3 2.7 0.16 0.7 1.2 0.78
Abdominal pain (%) 16.7 9.2 <0.001 7.0 4.0 0.06 3.4 3.5 0.94 5.0 3.7 0.41
Hear palpitations (%) 9.8 5.1 0.008 5.5 4.2 0.38 5.8 8.0 0.61 4.6 7.3 0.88
Back ache (%) 10.9 8.9 0.32 7.0 7.7 0.53 5.8 8.0 0.22 4.6 7.3 0.15
In bold P value < 0,05; Other symptoms had low frequency or were not significantly different at day 3. Fisher exact (2-tailed) used where indicated. No significant differences at day 45 (data not shown). NS 
= not significant/NA = not applicable. * Haemoglobine day 14 and day 45 (P value: Barlett's test)Malaria Journal 2006, 5:73 http://www.malariajournal.com/content/5/1/73
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lance system and raises questions about the useful thera-
peutic life (UTL) of this ACT combination. Indeed, it has
already been suggested that the optimal future ACT com-
bination might be a 3-drug ACT including 2 synergistic
quinolone drugs with similar, relative long-lives protect-
ing each other's efficacy after the fast elimination of the
artemisinin derivative [19].
In Zambia, HIV-1 prevalence is estimated at 25.2 %
among mothers attending the antenatal clinic [20]. HIV-1
infected adults have a higher risk of malaria infection,
clinical malaria and treatment failure and this is inversely
related to the absolute CD4 cells count [21-23]. Further-
more, some classes of antiretrovirals (protease inhibitors)
might interfere with the physiopathology of malaria or
with the metabolic pathways of antimalarial drugs [24].
In areas where both diseases are highly endemic this
might have an impact on the UTL of a newly introduced
ACT such as AL. The need to improve absorption of AL by
co-administering it with a fatty meal and a three day, twice
daily, regimen remains a concern in resource-poor set-
tings.
Conclusion
In conclusion, this study, despite the incompletely super-
vised treatment, confirmed the excellent efficacy and
safety/tolerability of the six-dose AL in adults. Next to
pharmacovigilance, further research is still needed to
ensure its correct deployment, possibly to pregnant
women.
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